Cytogenetic clonal heterogeneity is not an independent prognosis factor in 15-60-year-old AML patients: results on 1291 patients included in the EORTC/GIMEMA AML-10 and AML-12 trials.

Fréderic BaronMarian Stevens-KroefMichal KicinskiGiovanna MeloniPetra MuusJean-Pierre MarieConstantijn J M HalkesXavier ThomasRadovan VrhovacGiorgina SpecchiaFrancois LefrereSimona SicaMarco ManciniAdriano VendittiAnne HagemeijerHeiko BeckerJoop H JansenSergio AmadoriTheo de WitteRoelof WillemzeStefan Suciu

Published in: Annals of hematology (2018)

AML-10: ClinicalTrials.gov identifier: NCT00002549, retrospectively registered July 19, 2004; AML12: ClinicalTrials.gov identifier: NCT00004128, registered January 27, 2003.

Keyphrases

acute myeloid leukemia
end stage renal disease
newly diagnosed
ejection fraction
allogeneic hematopoietic stem cell transplantation
peritoneal dialysis
prognostic factors
single cell